Predictions
Sanofi S.A.
Start price
Target price
Perf. (%)
€79.36
11.08.22
11.08.22
€110.00
11.08.23
11.08.23
22.37%
12.08.23
12.08.23
Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Future proof or reliable business model
Cellectis Nom.
Start price
Target price
Perf. (%)
€3.52
07.08.22
07.08.22
€3.80
07.08.23
07.08.23
-52.13%
08.08.23
08.08.23
Could be worthwhile Investment >10% per year
Abivax S.A.
Start price
Target price
Perf. (%)
€9.10
04.08.22
04.08.22
-
04.08.23
04.08.23
81.32%
05.08.23
05.08.23
Could be very worthwhile Investment >20% year
EssilorLuxottica SA
Start price
Target price
Perf. (%)
€157.25
29.07.22
29.07.22
€200.00
29.07.23
29.07.23
14.87%
30.07.23
30.07.23
Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Future proof or reliable business model
Valneva SE
Start price
Target price
Perf. (%)
€9.82
21.07.22
21.07.22
-
21.07.23
21.07.23
-30.16%
22.07.23
22.07.23
Revenue growth >5% per year expected
Could be very worthwhile Investment >20% year
High valuation
Growths slower than the competition
EssilorLuxottica SA
Start price
Target price
Perf. (%)
€146.15
15.07.22
15.07.22
€175.00
15.07.23
15.07.23
21.16%
16.07.23
16.07.23
Poxel S.A.
Start price
Target price
Perf. (%)
€2.49
20.08.22
20.08.22
-
20.08.23
20.08.23
-75.54%
07.06.23
07.06.23
Could be worthwhile Investment >10% per year
Valneva SE
Start price
Target price
Perf. (%)
€10.23
09.08.22
09.08.22
€14.00
09.08.23
09.08.23
-46.91%
30.05.23
30.05.23
Small cyclical dependencies
Below average Marketposition
Few uniques
Sanofi S.A.
Start price
Target price
Perf. (%)
€85.88
28.10.22
28.10.22
-
28.10.23
28.10.23
16.27%
18.05.23
18.05.23
Risky Investment
Abivax S.A.
Start price
Target price
Perf. (%)
€8.30
02.09.22
02.09.22
€5.00
31.12.24
31.12.24
85.30%
08.05.23
08.05.23
Could be very worthwhile Investment >20% year
Sanofi S.A.
Start price
Target price
Perf. (%)
€79.94
11.08.22
11.08.22
€63.00
30.09.24
30.09.24
26.47%
08.05.23
08.05.23
Could be worthwhile Investment >10% per year
Sanofi S.A.
Start price
Target price
Perf. (%)
€88.01
01.11.22
01.11.22
€100.00
31.12.24
31.12.24
13.11%
05.05.23
05.05.23
Could be worthwhile Investment >10% per year
Novacyt S.A.
Start price
Target price
Perf. (%)
€1.06
05.09.22
05.09.22
-
05.09.23
05.09.23
-46.97%
24.04.23
24.04.23
Probably not worthwhile Investment
Gensight Biologics SA
Start price
Target price
Perf. (%)
€2.34
07.04.22
07.04.22
-
07.04.23
07.04.23
-1.02%
08.04.23
08.04.23
Could be worthwhile Investment >10% per year
Orpea Nom.
Start price
Target price
Perf. (%)
€2.17
08.02.23
08.02.23
-
08.02.24
08.02.24
-9.35%
03.04.23
03.04.23
Could be very worthwhile Investment >20% year
Gensight Biologics SA
Start price
Target price
Perf. (%)
€2.97
07.03.22
07.03.22
-
07.03.23
07.03.23
-19.53%
08.03.23
08.03.23
Risky Investment
Innate Pharma
Start price
Target price
Perf. (%)
€2.51
07.03.22
07.03.22
-
07.03.23
07.03.23
21.39%
08.03.23
08.03.23
Probably not worthwhile Investment
Orpea Nom.
Start price
Target price
Perf. (%)
€2.58
20.02.23
20.02.23
-
20.02.24
20.02.24
-1.16%
05.03.23
05.03.23
Could be very worthwhile Investment >20% year
Sartorius Stedim Biotech S.A.
Start price
Target price
Perf. (%)
€328.00
20.02.22
20.02.22
€400.00
20.02.23
20.02.23
1.01%
21.02.23
21.02.23
Could be worthwhile Investment >10% per year
Orpea Nom.
Start price
Target price
Perf. (%)
€2.87
05.02.23
05.02.23
-
05.02.24
05.02.24
-10.07%
18.02.23
18.02.23
Could be very worthwhile Investment >20% year
Orpea Nom.
Start price
Target price
Perf. (%)
€2.36
07.02.23
07.02.23
€4.00
07.02.24
07.02.24
9.32%
18.02.23
18.02.23
Could be very worthwhile Investment >20% year
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation
Innate Pharma
Start price
Target price
Perf. (%)
€3.24
10.02.22
10.02.22
€3.80
10.02.23
10.02.23
-4.81%
11.02.23
11.02.23
Could be worthwhile Investment >10% per year
Valneva SE
Start price
Target price
Perf. (%)
€15.03
05.02.22
05.02.22
€20.00
05.02.23
05.02.23
-57.41%
06.02.23
06.02.23
Revenue growth >5% per year expected
Differentiated customer and product portfolio
Good culture
Could be very worthwhile Investment >20% year